Kornimate/medical-research-clean huggingface dataset:
hepatic fibrosis non-invasive methods questionnaire

Conditions: Cirrhosis; Fibrosis

Summary: due to the limitations and the invasive nature of liver biopsy, there has been extensive interest in developing non-invasive tests to measure liver fibrosis (1). these are alternatives to liver biopsy that can be used in clinical practice, with benefits in terms of cost, risk, and patient convenience (2). clinically applicable non-invasive tests include radiological studies, transient elastography (te), and serum markers. we aim at studying acceptability, reliability, applicability and practical aspects of invasive and noninvasive methods for assessment of hepatic fibrosis and cirrhosis among hepatologists.

due to the limitations and the invasive nature of liver biopsy, there has been extensive interest in developing non-invasive tests to measure liver fibrosis (1). these are alternatives to liver biopsy that can be used in clinical practice, with benefits in terms of cost, risk, and patient convenience (2). clinically applicable non-invasive tests include radiological studies, transient elastography (te), and serum markers. we aim at studying acceptability, reliability, applicability and practical aspects of invasive and noninvasive methods for assessment of hepatic fibrosis and cirrhosis among hepatologists. methods: the study is a survey study among hepatologists. four thousand hepatologists will be invited to participate in the questionnaire through e-mail invitations to answer 50 questions of the questionnaire. the questionnaire will be hosted on survey monkey website and results will be analyzed to get the consensus opinion of participants for the use of invasive and non-invasive methods for assessment of hepatic fibrosis and cirrhosis and factors affecting their preferences. statistical analysis plan analysis of data will be performed using statistical package for scientific studies 17 for windows. description of qualitative variables will be in the form of numbers (no.) and percent (%). description of quantitative variables will be in the form of mean, standard deviation (sd). questionnaire results will be compared against different baseline characteristics of the studied group. according to the type and distribution of data, suitable tests for inferential statistics will be used. significance of the results will be presented in the form of p-value.

Eligibility criteria:
inclusion criteria: * hepatologists exclusion criteria: * non hepatologists
effect of probiotic limosilactobacillus reuteri (l. reuteri) on crying and fussing time in infants with colic

Conditions: Infantile Colic

Summary: this is a double-blind, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying and fussing time.


Eligibility criteria:
inclusion criteria: 1. aged between 3-12 weeks at screening. 2. gestational age 37+0 weeks - 42+0 weeks at birth. 3. birth weight appropriate for gestational age (aga - weight between 10th and 90th percentile) or large for gestational age (lga - weight above the 90th percentile) determined using who weight-for age percentile guides. 4. parents/caregivers/legal guardians are \>18 years. 5. exclusively or predominantly breastfed infants (\> 50 % breast fed). 6. willing to maintain current feeding patterns (not change formula/not change ratio of formula:breast milk etc.). 7. readiness and the opportunity for parents/caregivers/legal guardians to fill out a study diary, questionnaires. 8. infantile colic diagnosed according to rome iv criteria (face-to-face consult with a physician, parents/caregivers/legal guardians must report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). at visit 2, this will be confirmed by baby's day diary®, at least one 24-hour period should show 3 or more hours of crying/fussing time. 9. parents/caregivers/legal guardians with ability to understand and comply with the requirements of the study, as judged by the investigator. 10. parents/caregivers/legal guardians willing and able to give informed consent for their and their infant's participation in the study. 11. the mother of the infant must be willing to attend visit 2 (day 0), visit 3 (day 8), and visit 4 (day 22). 12. infant is considered healthy, in the opinion of the investigator following physical exam. exclusion criteria: 1. infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk \> 8 times daily, projectile, bilious or bloody emesis). 2. infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container \> 12x in breastfed and \>5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents/caregivers/ legal guardians. 3. infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease. 4. infants with reported exposure to probiotics in the 7 days prior to screening visit (v1) and throughout the study period. 5. infants with reported exposure to oral and/or systemic antibiotics in the 7 days prior to screening visit (v1) and throughout the study period. 6. infants with reported exposure to medications, therapies, or products with the aim to relieve infantile colic including proton pump inhibitors in the 7 days prior to screening visit (v1) and throughout the study period.
a study of ly3885125 in participants with dyslipidemia or non-alcoholic fatty liver disease (nafld)

Conditions: Dyslipidemias; Non-Alcoholic Fatty Liver Disease

Summary: the main purpose of this study is to evaluate the safety and tolerability of ly3885125 after administration of single ascending doses in participants with dyslipidemia (part a) and multiple doses in participants with non-alcoholic fatty liver disease (part b). blood tests will be performed to check how much ly3885125 gets into the bloodstream and how long it takes the body to eliminate it. the study will last up to approximately 49 weeks for part a and 62 weeks for part b, for a total of approximately 111 weeks.


Eligibility criteria:
inclusion criteria: parts a \& b * males, or females of not of childbearing potential, * on a stable diet for the 3 months prior to randomization and willing to continue the same stable diet during the study. part a * dyslipidemia with the following fasted blood levels at screening: 150 mg/dl ≤ triglycerides \<500 mg/dl, and ldl-cholesterol ≥100 mg/dl, * body mass index (bmi) in range of 18.5 to 45.0 kg/m2. part b * nafld with liver fat content ≥8% as determined by magnetic resonance imaging proton density fat fraction (mri-pdff), * bmi in range of 27 to 45.0 kg/m2 exclusion criteria: parts a \& b * history or presence of medical illness including, but not limited to, any cardiovascular, thromboembolism or bleeding disorder, hepatic, respiratory, hematological, endocrine, immune, psychiatric, or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation, * uncontrolled hypertension with a resting blood pressure ≥ 160 mmhg systolic or ≥ 100 mmhg diastolic at visit 1, * alanine transaminase (alt) or aspartate aminotransferase (ast) \>3.0 × uln for the reference range, * alkaline phosphatase (alp) \>1.5 × uln for the reference range, * total bilirubin (tbl) \>1.5 × uln for the reference range, * taken drugs associated with hepatic steatosis (e.g., amiodarone, valproic acid, methotrexate, tamoxifen) for more than 2 weeks in the 3 months prior to screening visit, * type 1 diabetes mellitus (t1dm) or any other type of diabetes mellitus other than t2dm, * poorly controlled t2dm with glycated hemoglobin (hba1c) of \>9.0%, * treatment with glp-1 ra and gip/glp-1 ra and approved or experimental agents that target pcsk9 within 9 months prior to screening visit. part b * evidence of other forms of chronic liver disease, * initiated treatment with, or changed dose of, medications that may cause significant weight gain or weight loss, within 3 months prior to the screening visit, * have a self-reported change in body weight \>5 kg (11 pounds) within 3 months prior to screening visit
the efficacy and safety of indobufen and low-dose aspirin in different regimens of antiplatelet therapy

Conditions: Coronary Atherosclerosis

Summary: a total of 210 coronary atherosclerosis patients without indications for stent implantation are included. the baseline values of platelet aggregation rate, plasmathromboxaneb2 and urinary 11-dh thromboxaneb2 are measured by light transmittance aggregometry method and elisa after aspirin 100 mg /d ≥5d. then the patients are randomly divided into 7 groups: group1: aspirin 100 mg/d; group2: aspirin 100 mg /2d; groups3: aspirin 100 mg / 3d; groups4: morning 50mg evening 50mg; group5: aspirin 75mg / d; group6: aspirin 50mg / d; group7: indobufen100mg bid. one month later,arachidonic acid-induced platelet aggregation rate , plasma txb2 and urine 11-dh txb2 are analyzed again. all patients are followed-up for 1 year. the stomach intestinal reactions, small bleeding events are recorded.

a total of 210 coronary atherosclerosis patients without indications for stent implantation are included. exclusion criteria：aspirin resistance, uncontrolled hypertension (\> 160 / 100mmhg),hemoglobin concentration \<100g /l, hemorrhagic disease or a history of bleeding tendency, taking other nonsteroidal drugs, severe liver disease history, malignant tumor, active gastric mucosa bleeding, percutaneous coronary intervention history, coronary artery bypass surgery, cardiac function grade ⅳ.the baseline values of platelet aggregation rate, plasma txb2 and urinary 11-dh txb2 are measured by lta method and elisa after aspirin 100 mg /d ≥5d. then the patients are randomly divided into 7 groups: group1: aspirin 100 mg/d; group2: aspirin 100 mg /2d; groups3: aspirin 100 mg / 3d; groups4: morning 50mg evening 50mg; group5: aspirin 75mg / d; group6: aspirin 50mg / d; group7: indobufen100mg bid. one month later,arachidonic acid-induced platelet aggregation rate , plasma txb2 and urine 11-dh txb2 are analyzed again. all patients are followed-up for 1month,6months and1 year. the stomach intestinal reactions, small bleeding events ,whether to take proton pump inhibitors are recorded.

Eligibility criteria:
inclusion criteria: clinical diagnosis of coronary atherosclerosis without indications for stent implantation . patient aged \>18 years and ≤75years. must be able to swallow tablets exclusion criteria: aspirin resistance; uncontrolled hypertension (\> 160 / 100mmhg); hemoglobin \<100g / l; hemorrhagic disease or bleeding tendency history; taking other non-steroidal drugs; severe liver disease history; malignant neoplasms; active gastric mucosa bleeding; pci history; coronary artery bypass surgery; cardiac function grade ⅳ.

Keywords: light transmittance aggregometry indobufen aspirin plasma thromboxane urine 11-dehydro thromboxane
pilates mat versus segmental control exercises in patients with chronic non-specific low back pain

Conditions: Chronic Non-Specific Low Back Pain

Summary: this study sought to determine the effect of pilates exercises versus segmental control exercises on spinopelvic angles, pain intensity, and functional disability in patients with chronic non-specific low back pain.

low back pain (lbp) is the most common musculoskeletal condition and constitutes a global public health problem. the majority of patients (up to 90%) are categorized as having nonspecific low back pain, which is described as symptoms lack of clear particular reasons, i.e., beginning of low back pain is not known. many clinical guidelines and systematic reviews have recommended exercise therapy as one of the preferred treatments at decreasing pain and improving function in nslbp. in the last decade, the pilates method has become one of the most popular exercise programmes incorporated in clinical practice. therapeutic exercises, specifically segmental control exercises, decrease pain, reduce disability, improve quality of life, increase muscular endurance and strength, improve segmental stability, and reduce risk of injury. studies have shown that both segmental control exercises and pilate's exercises are effective in the management of pain and disability in individuals with chronic lbp. however, it appears there is dearth of empirical data establishing which is more effective between the segmental control exercises and pilates exercises on individuals with non-specific chronic low back pain. thus, there exist certain gaps involving the two therapeutic techniques. therefore, this study sought to determine the effect of pilates exercises versus segmental control exercises on spinopelvic angles, pain intensity, and functional disability in patients with chronic non-specific low back pain.

Eligibility criteria:
inclusion criteria: * age group: 18 to 65 years. (yentür et al., 2021) * both male and female gender will be included in the study. (akhtar et al., 2017) * nonspecific, non-radicular (axial) chronic lbp diagnosis with hyperlordosis (lbp for at least three months). (kızıltaş et al., 2022) * visual analog scale (vas) score of 3 or higher. (mannion et al., 2009) exclusion criteria: * patients with acute attacks of lbp. (caglayan et al.,2014) * pain referred from the lumbar to the lower extremities. * serious spinal disorder including malignancy, osteoporosis, ankylosing spondylitis, cauda equina compression, and infection. * fracture of vertebrae, and administered epidural injection. (sarker et al., 2020) * pregnancy and feeding * structural abnormalities in the lumbar region * surgical history in the lumbar spine area * heart disease. (kızıltaş et al., 2022) * history of vestibular dysfunction * regular pilates/any other specific exercise program in the last 3 months. (mehta et al.,2022)
brain, psychological and epigenetic determinants for optimizing the treatment of chronic low back pain

Conditions: Chronic Low-back Pain

Summary: the goal of this observational study is to better understand the role of the brain in chronic low back pain patients.

chronic pain affects millions of people worldwide, and the main cardinal sign of any arthritis condition is pain. several arthritis conditions can cause chronic low back pain (clbp).the mechanisms that contribute to clbp are not yet fully understood, but considering the role of the brain in the context of chronic pain, it is only logical to investigate structural and functional brain properties in clbp, in order to improve diagnosis and treatment of this condition.

Eligibility criteria:
inclusion criteria: * low back pain (≥ 6 months) with or without pain radiating to the legs or radiating to the neck * positive medial branch blocks, suggesting that the pain originates from the lumbar facet joints * average pain intensity of ≥ 3/10 in the 24-hour period before the initial visit * pain primarily localized in the lower back exclusion criteria: * inadequate pain relief or relief of less than three months following selective thermoablation of medial lumbar branches by radiofrequency * neurological, cardiovascular, or pulmonary disorders * comorbid pain syndrome * history of surgical intervention in the back * a corticosteroid infiltration within the past year * pregnancy (current or planned during the course of the study) * contra-indication to magnetic resonance imaging (mri)
comparison of cruciate retaining and posterior stabilized total knee arthroplasty

Conditions: Osteoarthritis, Knee; Arthropathy of Knee Joint

Summary: several authors and large registries have suggested the potential for an increased risk of all-cause revision with the use of posterior cruciate-substitution (ps) total knee arthroplasty (tka). the purpose of the current study was to compare posterior cruciate retaining (cr) and ps implants with respect to the functional and radiographic results, prevalence of osteolysis, revision rates and survivorship.

the supremacy debate between posterior cruciate-retaining (cr) and posterior stabilized (ps) total knee arthroplasty (tka) has now entered into the 4th decade. multiple research studies have investigated cr and ps tkas on the basis of kinematic, clinical, radiographic, and survivorship analysis. despite arguments in favor of cr or ps tka designs, several short or mid-term studies have shown no difference in functional outcomes between these two designs. considering the fact that cr and ps tka fare equally at short-term and mid-term, the decision to select either design should depend on their long-term survivorship. there have been few long-term survivorship analysis that have directly compared cr and ps tkas with aseptic revision for any reason as the end point. these long-term studies of cr and ps tka have been done independently. a comparison of the results in the same patients eliminates the variability that is introduced by differences in gender, age, weight, comorbidity, bone quality, and activity level and allows for a meaningful comparison of the impact of fixation on the outcome of tka. however, variability in terms of the preoperative severity of arthritis cannot be eliminated because of the design on both sides is rarely identical. the purpose of this study was to identify differences in implant survivorship between cr and ps tkas in patients with osteoarthritis who were younger than 65 years of age and cr implant in one knee and ps implant in the other.

Eligibility criteria:
inclusion criteria: * end-stage osteoarthritis of the knee joint requiring total knee arthroplasty with bilateral disease exclusion criteria: * inflammatory disease * patient with other lower extremity disease which may affect functional outcome * neurologic disease effecting patients lower extremity * revision surgery * patient not medically cleared for bilateral surgery
promoting safe use of children's cough/cold medicines

Conditions: Cough

Summary: this study seeks to identify ways to help parents safely use cough/cold medications with their children. the study focuses on 3 key tasks that have been found to be difficult for parents: 1) decision-making about whether medicines should be given based on a child's age, 2) use of active ingredient information to determine which medications are safe to give together, and 3) medication dosing. specific ways that labels and dosing tools can be changed to improve parent understanding and ability to use pediatric cough and cold medications will be tested. this includes looking at whether including age restriction information on the front panel helps parents make better decisions about whether a medication should be given to a child, as well as whether presence of a specific warning or pictogram can help improve this understanding. in addition, the role of font size, including a box around ingredients, and use of a specific warning to look at and compare active ingredients, will be examined to see if these can help parents decide if two medications can be given together safely. finally, dosing charts with pictograms of dosing tools, and provision of certain dosing tools, can lead to fewer parent dosing errors. a label/dosing tool combination that incorporates what is learned from the first part of the study will be developed based on findings from the first part of the study, and then tested to see whether this improves parent understanding and use of pediatric cough and cold medicines. hypotheses include: 1) changes in labels and dosing tools, such as including explicit warnings, and pictographic warnings/instructions can improve parent understanding and ability to act on of medication instructions, 2) parents with low health literacy and/or lep will especially benefit from strategies such as explicit wording, warnings, and pictogram, and 3) parents receiving the comprehensive labeling and dosing strategy will have a better understanding of appropriate use of cough/cold medications, including fewer dosing errors, compared to standard labels. a multi-part experiment will be conducted. findings will be merged with known evidence around health literacy best practices to develop a comprehensive, consumer-centered strategy for english and spanish-speaking parents. pilot testing of the comprehensive strategy in comparison to existing labels will then take place.

see brief summary.

Eligibility criteria:
inclusion criteria: * parent/legal guardian 18 years or older * parent/legal guardian with children \<6 years old * english or spanish speaking exclusion criteria: * visual acuity worse than 20/50 (rosenbaum pocket screener) * uncorrectable hearing impairment * parents/ children too ill to participate will also be excluded
icg to assess ovarian perfusion

Conditions: Fibroid Uterus; Endometriosis; Uterus Myoma; Uterine Fibroid; Uterine Adenomyosis; Endometrial Cyst; Uterine Cyst

Summary: to assess the feasibility of using intravenous icg to characterize the vascular perfusion of ovaries during gynecologic surgery

the purpose of this study is to determine the feasibility of intravenous icg administration to facilitate assessments of ovarian vascular perfusion. historically, assessment of ovarian perfusion has been performed visually or via ultrasound with doppler evaluation. in patients with ovarian endometriomas, evidence of ovarian interstitial microvascular injury has been demonstrated similarly by the presence of low flow and high ri. the use of icg to evaluate ovarian perfusion specifically has not been reported. the use of icg for intraoperative perfusion assessment of the ovary could provide more information about the health of the ovary and inform the surgical approach to ovarian pathology. icg will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. near infrared fluorescence imaging will be used to illuminate the icg. the extent of perfusion will be determined using digital imaging software.

Eligibility criteria:
inclusion criteria: * patients attending a preoperative visit at the center for comprehensive gynecology who will undergo surgery. exclusion criteria: * not able to comprehend and sign a written consent * patients with a history of allergy to iodides * patients history of renal failure or uremia, and those on dialysis